CA2755499A1 - Protection of normal cells - Google Patents

Protection of normal cells Download PDF

Info

Publication number
CA2755499A1
CA2755499A1 CA2755499A CA2755499A CA2755499A1 CA 2755499 A1 CA2755499 A1 CA 2755499A1 CA 2755499 A CA2755499 A CA 2755499A CA 2755499 A CA2755499 A CA 2755499A CA 2755499 A1 CA2755499 A1 CA 2755499A1
Authority
CA
Canada
Prior art keywords
sulindac
epimer
derivatives
damage
structural analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2755499A
Other languages
English (en)
French (fr)
Inventor
Herbert Weissbach
Nathan Brot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHS Pharma Inc
Original Assignee
Florida Atlantic University
New York Society for Relief of Ruptured and Crippled
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Atlantic University, New York Society for Relief of Ruptured and Crippled filed Critical Florida Atlantic University
Publication of CA2755499A1 publication Critical patent/CA2755499A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2755499A 2008-05-05 2009-05-04 Protection of normal cells Abandoned CA2755499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/115,331 2008-05-05
US12/115,331 US8487128B2 (en) 2002-11-26 2008-05-05 Protection of normal cells
PCT/US2009/042703 WO2009137400A2 (en) 2008-05-05 2009-05-04 Protection of normal cells

Publications (1)

Publication Number Publication Date
CA2755499A1 true CA2755499A1 (en) 2009-11-12

Family

ID=41265328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2755499A Abandoned CA2755499A1 (en) 2008-05-05 2009-05-04 Protection of normal cells

Country Status (7)

Country Link
US (2) US8487128B2 (enExample)
EP (1) EP2282733A4 (enExample)
JP (1) JP2011520808A (enExample)
CN (1) CN102112124A (enExample)
AU (1) AU2009244500A1 (enExample)
CA (1) CA2755499A1 (enExample)
WO (1) WO2009137400A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
CA2696627C (en) 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2882426A1 (en) * 2012-08-13 2015-06-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treatment of cystic fibrosis
KR102354613B1 (ko) 2012-11-15 2022-01-21 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
JP6295278B2 (ja) * 2013-02-28 2018-03-14 アニダ ファーマ インコーポレイテッド 聴器毒性を治療する方法
WO2014160702A1 (en) 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
JP6464166B2 (ja) 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
JP6735225B2 (ja) * 2015-12-25 2020-08-05 共栄化学工業株式会社 皮膚外用組成物及び経口組成物
US11186534B2 (en) * 2017-03-17 2021-11-30 University Of South Alabama Derivatives of sulindac can protect normal cells against oxidative damage
PL237474B1 (pl) * 2017-05-04 2021-04-19 Wyzsza Szkola Medyczna W Bialymstoku Nowe zastosowanie kwasu 2-[(3Z)-6-fluoro-2-metylo-3-[(4-metylosulfinylofenylo) metylideno]inden-1-ylo] octowego
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053429A (en) 1988-04-08 1991-10-01 The Lithox Corporation, Inc. Treating inflammatory pain with methionine
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
US5608067A (en) 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
EP1469884A1 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
AU2003298020A1 (en) * 2002-11-26 2004-06-18 Florida Atlantic University Catalytic antioxidants and methods of use
WO2007130575A2 (en) 2006-05-03 2007-11-15 Florida Atlantic University Protection against oxidative damage in cells

Also Published As

Publication number Publication date
US8871971B2 (en) 2014-10-28
EP2282733A2 (en) 2011-02-16
US20090326073A1 (en) 2009-12-31
US20140018429A1 (en) 2014-01-16
CN102112124A (zh) 2011-06-29
AU2009244500A1 (en) 2009-11-12
EP2282733A4 (en) 2012-12-12
US8487128B2 (en) 2013-07-16
JP2011520808A (ja) 2011-07-21
WO2009137400A2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
US8487128B2 (en) Protection of normal cells
US20090069428A1 (en) Catalytic antioxidants and methods of use
JP4160115B2 (ja) 疾患の予防及び治療のための酸化防止剤として有用な合成触媒遊離基スカベンジャー
JP2021167358A (ja) 重水素化化合物およびその使用
EP3500256A1 (en) Aldehyde trapping compounds and uses thereof
JP2008538586A (ja) 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2004514724A (ja) 環状サレン−金属化合物：疾患の処置及び予防において抗酸化剤として有用な反応性酸素種スカベンジャー
EP0939654A1 (fr) Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene
EP2868662A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
PT99014B (pt) Processo para a preparacao de novos derivados isoprenoides inibidores da fosfolipase a2 e de composicoes farmaceuticas que os contem
WO1996040127A1 (en) Nitroxides as protectors against oxidative stress
EP2010164A1 (en) S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US20140315989A1 (en) Apocynin-lipoic acid conjugates and uses thereof
Mason et al. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids
WO2007121545A1 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
JP7699551B2 (ja) コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
CN105142400B (zh) 防腐体系
JP2015160847A (ja) 小分子のキサンチンオキシダーゼ阻害剤および使用方法
EP4101839A1 (en) Compound and use thereof
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
MASON12 et al. A BIOLOGICAL RATIONALE FOR THE CARDIOTOXIC EFFECTS OF ROFECOXIB
EA045539B1 (ru) Сукцинатное пролекарство, композиции, содержащие сукцинатное пролекарство, и их применение
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150505